CD4 and neoplasm: In the phase II study of T-Vec in melanoma, post-treatment tumor biopsies were obtained, and treated patients were observed to have lower levels of immunosuppressive cell types including CD4 + FOXP3+ regulatory T-cells and myeloid derived suppressor cells (MDSCs) within the TME of injected lesions as compared to reference controls [5].